Evidence map›Paper›PMID 22684561›Full record

ArticleJournal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban2012

Inhibitory effects of microRNA-34a on cell migration and invasion of invasive urothelial bladder carcinoma by targeting Notch1.

Chao Zhang, Zhiyong Yao, Mingyang Zhu, Xin Ma, Taoping Shi, Hongzhao Li, Baojun Wang, Jinzhi Ouyang, Xu Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. MicroRNAs and target molecules in bladder cancer.Medical oncology (Northwood, London, England) · 2020
    Review
  4. Article
  5. Article
  6. MicroRNAs: Key Players in Bladder Cancer.Molecular diagnosis & therapy · 2019
    Review
  7. Review
  8. Review
  9. Article
  10. The role of microRNAs in bladder cancer.Investigative and clinical urology · 2016
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2013
    Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Chao ZhangDepartment of Urology, Chinese PLA General Hospital, Beijing, 100853, China.
Zhiyong YaoDepartment of Urology, Air Force General Hospital of PLA, Beijing, 1000853, China.
Mingyang ZhuDepartment of Urology, Chinese PLA General Hospital, Beijing, 100853, China.
Xin MaDepartment of Urology, Chinese PLA General Hospital, Beijing, 100853, China.
Taoping ShiDepartment of Urology, Chinese PLA General Hospital, Beijing, 100853, China.
Hongzhao LiDepartment of Urology, Chinese PLA General Hospital, Beijing, 100853, China.
Baojun WangDepartment of Urology, Chinese PLA General Hospital, Beijing, 100853, China.
Jinzhi OuyangDepartment of Endocrinology, Chinese PLA General Hospital, Beijing, 100853, China.
Xu ZhangDepartment of Urology, Chinese PLA General Hospital, Beijing, 100853, China. xzhang@tjh.tjmu.edu.cn.
Chinese PLA General Hospital · CNAir Force General Hospital PLA · CNNankai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs or miRs) are a class of short, non-coding RNAs that participate in various oncological processes. This study aims to explore the roles of microRNA-34a (miR-34a) in invasive urothelial bladder carcinoma. miR-34a was transfected into bladder cancer cell lines 253J and J82. The miR-34a expression levels in tissues and cells were detected by using qRT-PCR. The Notch1 expression was detected by qRT-PCR and Western blotting. Cell migratory and invasive abilities were measured by Transwell chamber assay. Bioinformatics and luciferase assay were performed to predict and analyze the binding sites between miRNA-34a and Notch1. It was found that there was aberrant expression of miR-34a in bladder cancer tissues. Moreover, we revealed that ectopic expression of miR-34a suppressed cell migration and invasion, while forced expression of Notch1 increased cell migratory and invasive abilities. Finally, we observed that miR-34a transfection significantly down-regulated luciferase activity and reduced the mRNA and protein levels of Notch1. Our study concluded that microRNA-34a antagonizes Notch1 and inhibits cell migration and invasion of bladder cancer cells, which indicates the tumor-suppressive function of microRNA-34a in bladder cancer.

Indexed as

AdultAgedCell MovementDown-RegulationFemaleGene TargetingHumansMaleMicroRNAsMiddle AgedNeoplasm InvasivenessReceptor, Notch1TransfectionTumor Cells, CulturedUrinary Bladder NeoplasmsMicroRNAsMIRN34 microRNA, humanNOTCH1 protein, humanReceptor, Notch1

Identifiers

PMID22684561
OpenAlexW201692448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.